Skip to main content



After the initial acute phase of illness, we recommend a daily dose of ArtemiC ™ Rescue to promote a strong and balanced immune system.

This dietary supplement is made from natural extracts and is micellised by our patented MyCell ™ technology for optimal absorption and effectiveness. Daily use is also recommended for those who want to optimize their immune system’s response to foreign invaders. ArtemiC ™ Rescue is currently being tested in a clinical trial to determine its effectiveness against the long-term symptoms of post-COVID infection.

Clinical Trials

Through its partnership with MGC Pharmaceuticals, Inc.,  AMC Holdings will focus on the following products on the positioning of the following products, for which U.S. trials are in process.

CimetrA™ is a nano-micellar pharmaceutical synergetic composition consisting of Curcumin, Boswellia, Artemisinin (and optionally could include Cannabinoids and/or Nitroxides). The composition can be manufactured in liquids or in solid pharmaceutically acceptable carriers, has antioxidant, anti-inflammatory, immuno-modulating and anti-viral properties and can be designed for multiple therapeutic applications utilising self-nanoemulsifying drug delivery systems.

Preclinical and clinical results to date support the pharmaceutical composition of CimetrA® as an effective treatment for addressing anti-inflammation and Cytokine over-production (known as Cytokine Storm) in all tested COVID-19 patients.

CannEpil® is a phytocannabinoid derived IMP, designed to treat Drug Resistant Epilepsy with a high CBD, low THC formula. The Phase IIb clinical trial for CannEpil® has regulatory approval at the Schneider Children’s Medical Hospital in Israel and will focus on the safety and efficacy of CannEpil® as an add-on treatment for children and adolescents with treatment resistant epilepsy, also known as Refractory Epilepsy. This randomised placebo-controlled Phase IIb trial is targeting recruitment of more than 100 patients.

The agreement with AMC follows on from CannEpil® being added to the Primary Care Reimbursement Service in the Republic of Ireland (see announcement 14 June 2021), making it free of charge for Irish patients prescribed the treatment under the Medical Cannabis Access Program.

Approximately 50 million people worldwide suffer from epilepsy, with approximately 33% of adults, and 20-25% of children, suffering from Refractory Epilepsy (or Drug Resistant Epilepsy), which cannot be controlled with traditional anti-seizure medication, highlighting the size of the market for CannEpil®.

CogniCann® is a formulation of phytocannabinoids that has been developed with the specific aim of treating the symptoms of Dementia and Alzheimer’s. CogniCann® is currently undergoing a Phase II clinical trial at the University of Notre Dame in Perth, Western Australia which has 21 patients currently enrolled, and is designed to evaluate the potential behavioural benefits of CogniCann® on patients with Dementia and Alzheimer’s disease.

Close Menu